Julie B. Feder
2021 - Aura Biosciences
In 2021, Julie B. Feder earned a total compensation of $2.3M as Chief Financial Officer at Aura Biosciences, a 324% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $145,042 |
|---|---|
| Option Awards | $1,466,906 |
| Salary | $360,407 |
| Stock Awards | $367,500 |
| Total | $2,339,855 |
Feder received $1.5M in option awards, accounting for 63% of the total pay in 2021.
Feder also received $145K in non-equity incentive plan, $360.4K in salary and $367.5K in stock awards.
Rankings
In 2021, Julie B. Feder's compensation ranked 5,420th out of 12,415 executives tracked by ExecPay. In other words, Feder earned more than 56.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,420 out of 12,415 | 56th |
Division Manufacturing | 2,285 out of 5,505 | 59th |
Major group Chemicals And Allied Products | 993 out of 2,375 | 58th |
Industry group Drugs | 885 out of 2,096 | 58th |
Industry Biological Products, Except Diagnostic Substances | 218 out of 449 | 51st |
Source: SEC filing on April 28, 2022.
Feder's colleagues
We found two more compensation records of executives who worked with Julie B. Feder at Aura Biosciences in 2021.